Stock Recommendations for the Week of November 2, 2026
Motilal Oswal Wealth Management has identified key stock recommendations for the week beginning November 2, 2026. Among the top picks are BSE and Symbiotec Pharmalab, both of which show promising growth potential based on recent market analysis.
BSE is currently priced at Rs 351, with a target price of Rs 400, indicating a potential upside of 14%. The stock has seen a significant increase in its futures and options (F&O) notional average daily turnover (ADTO), which surged by 85% in October 2026 compared to the previous month. This growth is attributed to a partial reversal of the Centralized Access System (CAS) expected to take effect on December 7, 2026, which is anticipated to further enhance trading volumes.
For Your Trading Desk
Sponsor Spike Success.
The analysis suggests that BSE's premium turnover market share has exceeded 30%, and the premium-to-notional (P/N) ratio has improved significantly, indicating a robust trading environment. Analysts project a 27% compound annual growth rate (CAGR) for profit after tax (PAT) from FY26 to FY28, supported by strong volume trends and the anticipated benefits from the CAS reversal.
Exploring Symbiotec Pharmalab's Growth Potential and Market Position
Symbiotec Pharmalab is another recommended stock, currently priced at Rs 124, with a target price of Rs 1430, reflecting a potential upside of 15%. The company is diversifying its operations beyond its traditional steroidal active pharmaceutical ingredient (API) business, expanding into a comprehensive platform that includes fermentation-led contract development and manufacturing organization (CDMO) services and complex injectables. Symbiotec holds a significant global market share in corticosteroids and has established a strong customer base across multiple countries.
Investment Outlook for Symbiotec and BSE Stocks
The company's strategic focus on building capacity in precision fermentation and industrial biotechnology positions it well within a $50 billion addressable market. Analysts expect Symbiotec's revenue from CDMO services to grow substantially, projecting an increase to Rs 5.3 billion by FY29 from a mere Rs 11 million currently. With a cumulative capital expenditure of Rs 16.7 billion planned by FY27, the company is set to enhance its operational capabilities significantly.
Overall, both BSE and Symbiotec Pharmalab present compelling investment opportunities for the upcoming week, driven by strong market fundamentals and growth strategies. Investors are encouraged to consider these stocks as part of their portfolio for potential gains in the near term.
